All In MedTech

Device Trial Radar · NCT07556692

A Study of Home-use Brain Stimulation to Treat Bipolar Depression

Home-based Transcranial Direct Current Stimulation in Bipolar Depression: a Randomised, Double-blind, Placebo-controlled Trial

Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 212 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

212

Planned (sponsor's estimate)

Start

Apr 24, 2026

Primary completion

Apr 30, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
King's College LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
South London and Maudsley NHS Foundation Trust
First posted
Apr 29, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bipolar depression is a long-lasting and disabling condition, and many people continue to experience depressive symptoms despite standard treatments. Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation that uses a very small electrical current applied through the scalp and has shown promise as a treatment for depression. This study aims to find out whether a home-based tDCS device is effective and safe in reducing symptoms of bipolar depression when compared with a placebo (sham) treatment. The study will also look at how acceptable the treatment is to participants and how well people are able to use the device at home. Who can participate? Adult patients aged 18 years and over who have a diagnosis of bipolar disorder and are currently experiencing a depressive episode. What does the study involve? Participants must meet specific eligibility criteria, which will be assessed by the research team. People who do not meet the study criteria or for whom tDCS is not suitable will not be able to take part. Participants will be randomly assigned to receive either active tDCS or a placebo (sham) treatment. Neither the participant nor the researchers assessing outcomes will know which treatment has been assigned. Participants will use a study device at home over a defined treatment period and will complete a series of assessments at set time points. These include clinician-rated interviews and self-reported questionnaires about mood and well-being. Device use and adherence data will be collected electronically. Participants will also be monitored for any side effects throughout their involvement in the study. Although the study is multi-site, participation is primarily remote, with most study activities completed from the participant's home. What are the possible benefits and risks of participating? Participants may experience an improvement in depressive symptoms. Information gained from this study may help improve future treatments for bipolar depression. tDCS is generally well tolerated. Possible side effects include mild and temporary sensations such as tingling, itching, headache, or skin irritation at the electrode sites. All participants will be monitored for adverse events, and appropriate support will be available if needed. Where is the study run from? The study is run from King's College London in collaboration with NHS research sites across the UK. When is the study starting and how long is it expected to run for? April 2026 to October 2027 Who is funding the study? The National Institute for Health and Care Research (NIHR), UK. Who is the main contact? Professor Cynthia Fu, the Chief Investigator at King's College London, cynthia.fu@kcl.ac.uk

Conditions

  • Bipolar Disorder (BD)

Interventions

  • Flow FL-100 tDCS headsetDevice

    The Flow FL-100 tDCS device is an adjustable headset with the electrodes built in. It delivers low-intensity direct current through scalp electrodes, modulating cortical excitability in the dorsolateral prefrontal cortex (DLPFC). The device is portable and commercially available.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine clinical efficacy of a 10-week course of home-based tDCS for bipolar depression in terms of depressive symptoms as measured by clinician-rated MADRS score in active and sham treatment arms at week 10Time frame: From randomisation to the end of treatment at 10 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • South London and Maudsley NHS Foundation Trust

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.